StockNews.com Begins Coverage on BioLineRx (NASDAQ:BLRX)

StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a report released on Saturday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright lowered their target price on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, November 25th.

BioLineRx Stock Performance

NASDAQ:BLRX opened at $0.14 on Friday. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52. The stock has a 50-day simple moving average of $0.29 and a two-hundred day simple moving average of $0.50. The firm has a market capitalization of $10.98 million, a PE ratio of -0.62 and a beta of 1.46. BioLineRx has a 52-week low of $0.13 and a 52-week high of $1.44.

Institutional Investors Weigh In On BioLineRx

A number of hedge funds have recently made changes to their positions in the company. CVI Holdings LLC purchased a new stake in BioLineRx during the second quarter valued at $462,000. PVG Asset Management Corp purchased a new stake in BioLineRx in the 2nd quarter worth about $70,000. Finally, Atria Investments Inc lifted its stake in BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares during the last quarter. 1.56% of the stock is currently owned by hedge funds and other institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.